|
2. Etiologie
|
|
|
|
2.4 Etiologie - Portables, ondes e-m
|
|
|
|
2.5 Etiologie - Gènes
|
|
|
Our cancer risk is not written in the stars [Cancer World]
|
|
|
|
|
|
f
Tomasetti and Vogelstein had not used the words bad luck in their
paper on how variation in cancer risk among tissues can be explained by
the number of stem cell divisions, the media might not have covered
the story the way they did. In this interview with The Cancer Letter,
Bertram Kramer, head of Cancer Prevention at the US National Cancer
Institute, tries to clear up some of the confusion.
|
|
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
|
Pursuit of Cash Taints Promise of Gene Tests [NY Times]
|
|
|
|
|
|
Few
doubt that some genetic testing companies are doing valuable,
cutting-edge research — in cancer treatment, for example — that has the
potential to change the course of medicine. But many of the genetic
tests, which can cost $1,000 each, have not proved valuable in improving
patient care.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
6.1 Observation
|
|
|
|
6.10 Politiques
|
|
|
|
|
House Spending Bill to Eliminate AHRQ While Adding $1.1 Billion to NIH Budget [The Cancer Letter]
|
|
|
|
|
|
A
$153 billion spending bill that cleared a House subcommittee June 17
seeks to abolish the Agency for Healthcare Research and Quality, the
federal entity that funds patient-centered outcomes research and
monitors the manner in which medicine is practiced in the U.S. At the
same time, the bill proposes increasing the NIH budget to $31.2 billion,
a $1.1 billion above this year’s level and $100 million more than the
White House requested.
|
|
|
|
|
|
|
6.4 Médico-éco
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.7.1 Bioinformatique
|
|
|
|
|
6.9 Controverses
|
|
|
How medicine is broken, and how we can fix it [The BMJ]
|
|
|
|
|
|
Well
documented problems exist in the funding and prioritisation of
research, the conduct of trials, the withholding of results, the
dissemination of evidence, and its implementation with patients. Here we
briefly examine six domains where the academy could call for simple
practical improvements that would address legitimate concerns.
|
|
|
|
|
|